Abstract | PURPOSE: RESULTS: In the SKOV3ip1 model, both single-agent bevacizumab and etaracizumab reduced tumor growth by 52-63% (p < 0.05), while combined therapy reduced growth by 63-74% compared to either agent alone (p < 0.05). Furthermore, bevacizumab/ paclitaxel was superior to paclitaxel alone ( weight reduction by 53%, p < 0.05), but etaracizumab/ paclitaxel was not. Combining all three agents was more effective than either agent with paclitaxel (p < 0.05). Significantly, both bevacizumab and etaracizumab each sensitized the taxane-resistant SKOV3TRip2 cells to paclitaxel, reducing growth by 56-73% (p < 0.05). Both agents decreased proliferation and microvessel density, and increased apoptosis, alone and in combination with paclitaxel. In the HeyA8 model, there was significantly reduced growth with bevacizumab treatment, but not with etaracizumab, and combination therapy was not superior to bevacizumab alone. EXPERIMENTAL DESIGN: In vivo therapy experiments were conducted in chemo-sensitive (SKOV3ip1, HeyA8) and -resistant (SKOV3TRip2) ovarian cancer models. VEGF was targeted with bevacizumab and alpha(V)beta(3) with etaracizumab. Mice were treated with each agent alone, together, or in combination with paclitaxel for assessment of tumor growth. Tumor specimens were tested for proliferative index, microvessel density and apoptosis. CONCLUSIONS:
|
Authors | Tae Jin Kim, Charles N Landen, Yvonne G Lin, Lingegowda S Mangala, Chunhua Lu, Alpa M Nick, Rebecca L Stone, William M Merritt, Guillermo Armaiz-Pena, Nicholas B Jennings, Robert L Coleman, David A Tice, Anil K Sood |
Journal | Cancer biology & therapy
(Cancer Biol Ther)
Vol. 8
Issue 23
Pg. 2263-72
(Dec 2009)
ISSN: 1555-8576 [Electronic] United States |
PMID | 19829059
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Integrin alphaVbeta3
- RNA, Messenger
- Vascular Endothelial Growth Factor A
- vascular endothelial growth factor A, mouse
- Bevacizumab
- etaracizumab
- Paclitaxel
|
Topics |
- Angiogenesis Inhibitors
(therapeutic use)
- Animals
- Antibodies, Monoclonal
(administration & dosage)
- Antibodies, Monoclonal, Humanized
- Apoptosis
- Bevacizumab
- Blotting, Western
- Cell Proliferation
- Disease Models, Animal
- Drug Therapy, Combination
- Female
- Fluorescent Antibody Technique
- Immunoenzyme Techniques
- Immunoprecipitation
- Integrin alphaVbeta3
(antagonists & inhibitors, genetics, metabolism)
- Mice
- Mice, Nude
- Ovarian Neoplasms
(drug therapy, metabolism)
- Paclitaxel
(administration & dosage)
- RNA, Messenger
(genetics, metabolism)
- Reverse Transcriptase Polymerase Chain Reaction
- Tumor Cells, Cultured
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors, genetics, metabolism)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|